Seoul [South Korea], July 11 (ANI/Global Economic): SD Biosensor said on the 8th of July that it will acquire Meridian Bioscience, the US diagnostic manufacturer, for about 2 trillion won along with SJL Partners, a Korean private equity fund (PEF).

This is the largest merger and acquisition (M&A), in which a domestic pharmaceutical company acquires a foreign company, SD Biosensor said.

Also Read | Uber Files: Leaked Documents Reveal How The Cab Aggregator Broke Laws, Lobbied With Governments To Expand Globally.

SD Biosensor and SJL Partners will acquire a 100 per cent stake in Meridian. SD Biosensor will hold a 60% stake and SJL Partners a 40 per cent stake.

SJL Partners consists of US market experts from JP Morgan, and will help SD Biosensor successfully enter the US market after the acquisition, SD Biosensor explained.

Also Read | Elon Musk Pokes Fun at Twitter Over Filing Lawsuit Against Him After Musk Terminates $44 Billion Deal.

The two companies will jointly make an investment in a U.S. subsidiary to merge with Meridian.

Through the acquisition, SD Biosensor will speed up its entry into global markets, including the U.S. market, based on Meridian's distribution network in North America. Meridian's experience in FDA licensing is also expected to play a key role to expand SD Biosensor's global business. (ANI/Global Economic)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)